Navigation Links
Melanoma Drug Boosts Recurrence-Free Survival

Pegylated inteferon cut risk 15% but did not reduce overall mortality rates

FRIDAY, July 11 (HealthDay News) -- A chemically modified form of interferon improves the chances that melanoma patients will survive and have no recurrence of the skin cancer, according to a new report.

Dutch researchers, who published their findings in this week's edition of The Lancet, said their study found long-term treatment with pegylated IFNa2b cut the risk of a recurrence by 15 percent over a four-year period.

However, the patients' overall survival rates did not improve, and the treatment was discontinued in 30 percent of the 627 patients because of toxicity. The most common side effects in all patients were liver toxicity, fatigue and depression.

In an accompanying comment in The Lancet, two American doctors concluded that the treatment is still worthwhile, however.

"For the large group of patients with melanoma found in their sentinel node, we believe this regimen will be an attractive alternative to high-dose interferon. Some patients with macroscopic nodal disease who would not tolerate or accept high-dose interferon will also want to consider this approach," wrote Vernon Sondak, of the University of South Florida College of Medicine in Tampa, and Lawrence Flaherty, of the Wayne State University School of Medicine in Michigan.

More information

The National Cancer Institute has more about melanoma.

-- Kevin McKeever

SOURCE: The Lancet, news release, July 10, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Melanoma Diagnosis Often Delayed for Rural Poor
2. Melanoma drug revs immune cells but cancer cells ignore it
3. Promising drug combination may help those with ocular melanoma that has spread
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
6. New type of drug shows promise in attacking melanoma in an innovative way
7. Genes Unlock New Treatments for Deadly Melanoma
8. Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma
9. Researchers Hone in on Cancer Stem Cells for Melanoma
10. Melanomas may appear noticeably different than other moles
11. Melanomas Present Unique Appearance
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson Insurance and Financial Services, ... preparation services, is providing an update on a charitable event that began earlier ... is a locally recognized nonprofit that provides shelter and care for animals seeking ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... the certification process to promote standards of excellence for the field of eating ... for March 22 – 25, 2018 in Orlando, Florida at the Omni Resort ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes ... a mock evacuation of the facility as part of a disaster drill on October ... Hose EMS and Shelton City Emergency Manager, as well as the Connecticut Long ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Texas , Oct. 11, 2017  Caris Life ... focused on fulfilling the promise of precision medicine, today ... has joined Caris, Precision Oncology Alliance™ (POA) as its ... cancer centers, the St. Jude Crosson Cancer Institute will ... advance the use of tumor profiling, making cancer treatment ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
Breaking Medicine Technology: